Listed

Aktis Oncology, Inc.

AKTSNasdaqCIK 2035832HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$3.4m, Q2 FY2026
Operating income−$28.9m, Q2 FY2026
Net income−$24.1m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m1.4Revenue, period not labelled, three months to 2025-03-31$1.4m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure1.6Revenue, period not labelled, three months to 2025-06-30$1.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure3.2Revenue, Q1 FY2026, three months to 2026-03-31$3.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure3.4Revenue, Q2 FY2026, three months to 2026-06-30$3.4m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Research and development$m15.9Research and development, period not labelled, three months to 2025-03-31$15.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure18.6Research and development, period not labelled, three months to 2025-06-30$18.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure20.0Research and development, Q1 FY2026, three months to 2026-03-31$20.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure25.3Research and development, Q2 FY2026, three months to 2026-06-30$25.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Operating income$m(18.1)Operating income, period not labelled, three months to 2025-03-31−$18.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(21.0)Operating income, period not labelled, three months to 2025-06-30−$21.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(22.7)Operating income, Q1 FY2026, three months to 2026-03-31−$22.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(28.9)Operating income, Q2 FY2026, three months to 2026-06-30−$28.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Net income$m(15.0)Net income, period not labelled, three months to 2025-03-31−$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(18.1)Net income, period not labelled, three months to 2025-06-30−$18.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(18.3)Net income, Q1 FY2026, three months to 2026-03-31−$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(24.1)Net income, Q2 FY2026, three months to 2026-06-30−$24.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Diluted EPS$ per share(18.60)Diluted EPS, period not labelled, three months to 2025-03-31−$18.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(22.39)Diluted EPS, period not labelled, three months to 2025-06-30−$22.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(0.38)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(0.44)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Basic EPS$ per share(18.60)Basic EPS, period not labelled, three months to 2025-03-31−$18.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(22.39)Basic EPS, period not labelled, three months to 2025-06-30−$22.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(0.38)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(0.44)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure

Balance sheet

Cash and equivalents$82.5m, Q2 FY2026
Shareholders' equity$484.8m, Q2 FY2026
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported58.3Cash and equivalents, period not labelled, at 2025-03-31$58.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure110Cash and equivalents, period not labelled, at 2025-06-30$110.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure37.8Cash and equivalents, period not labelled, at 2025-12-31$37.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure372Cash and equivalents, Q1 FY2026, at 2026-03-31$371.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure82.5Cash and equivalents, Q2 FY2026, at 2026-06-30$82.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Current assets$mnot reportednot reportednot reported230Current assets, period not labelled, at 2025-12-31$230.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure544Current assets, Q1 FY2026, at 2026-03-31$543.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure525Current assets, Q2 FY2026, at 2026-06-30$524.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Total assets$mnot reportednot reportednot reported265Total assets, period not labelled, at 2025-12-31$264.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure577Total assets, Q1 FY2026, at 2026-03-31$576.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure558Total assets, Q2 FY2026, at 2026-06-30$557.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Current liabilities$mnot reportednot reportednot reported31.2Current liabilities, period not labelled, at 2025-12-31$31.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure27.9Current liabilities, Q1 FY2026, at 2026-03-31$27.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure32.1Current liabilities, Q2 FY2026, at 2026-06-30$32.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Total liabilities$mnot reportednot reportednot reported77.6Total liabilities, period not labelled, at 2025-12-31$77.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure70.7Total liabilities, Q1 FY2026, at 2026-03-31$70.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure72.8Total liabilities, Q2 FY2026, at 2026-06-30$72.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure
Shareholders' equity$m(87.8)Shareholders' equity, period not labelled, at 2024-12-31−$87.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(102)Shareholders' equity, period not labelled, at 2025-03-31−$101.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(118)Shareholders' equity, period not labelled, at 2025-06-30−$118.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure(146)Shareholders' equity, period not labelled, at 2025-12-31−$146.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure506Shareholders' equity, Q1 FY2026, at 2026-03-31$506.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure485Shareholders' equity, Q2 FY2026, at 2026-06-30$484.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure

Cash flow

Operating cash flow−$20.6m, Q2 FY2026
Capital expenditure$1.3m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(17.5)Operating cash flow, period not labelled, three months to 2025-03-31−$17.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(16.2)Operating cash flow, period not labelled, three months to 2025-06-30−$16.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349144. Derived: 6-month figure less the 3-month figure.Report this figure(24.2)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$24.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure(20.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$20.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349144. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m1.9Capital expenditure, period not labelled, three months to 2025-03-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure1.5Capital expenditure, period not labelled, three months to 2025-06-30$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349144. Derived: 6-month figure less the 3-month figure.Report this figure1.9Capital expenditure, Q1 FY2026, three months to 2026-03-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure1.3Capital expenditure, Q2 FY2026, three months to 2026-06-30$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349144. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)55.30m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.8Diluted shares (weighted), period not labelled, three months to 2025-03-31805,821 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure0.8Diluted shares (weighted), period not labelled, three months to 2025-06-30807,281 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure48.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3148,630,038 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216749.Report this figure55.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3055,300,107 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349144.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.